Engineered phage-silver nanoparticle complexes as a new tool for targeted therapies.

Area of Science:

• Biotechnology
• Nanotechnology
• Microbiology

Background:

• Antibiotic resistance necessitates novel therapeutic strategies.
• Bacteriophages offer targeted bacterial infection control.
• Silver nanoparticles possess antimicrobial properties.

Purpose of the Study:

• To develop and evaluate engineered phage-silver nanoparticle (AgNP) complexes for targeted antibacterial therapy.
• To assess the selective antimicrobial activity of AgNP@Li5 phage complexes against specific E. coli strains.
• To explore the potential for customizable targeted therapy by modifying phage display peptides.

Main Methods:

• Synthesis and characterization of silver nanoparticles (AgNPs).
• Engineering of M13 bacteriophages (Li5 phage) to display a specific peptide.
• Combination of AgNPs and engineered phages to form AgNP@Li5 molecular complexes.
• Evaluation of antibacterial activity and Minimum Inhibitory Concentration (MIC) against various E. coli strains and other bacteria.

Main Results:

• AgNP@Li5 complexes demonstrated highly selective antibacterial activity against E. coli F+, F-, and O157:H7 strains.
• Significant inhibition of E. coli TG1 and E. coli F- growth observed at a 1:16 dilution.
• Reduced but still present activity against E. coli O157:H7 at a 1:8 dilution.
• Minimal impact on non-target bacterial species (p < 0.0001).

Conclusions:

• Engineered phage-AgNP complexes provide a precise and targeted approach to combating bacterial infections.
• The specificity of this system minimizes collateral damage to the microbiome.
• The platform's modularity allows for customization to target various pathogens and potentially tumors.